<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04759040</url>
  </required_header>
  <id_info>
    <org_study_id>MIGRAINEGUARD</org_study_id>
    <nct_id>NCT04759040</nct_id>
  </id_info>
  <brief_title>Improvement of Migraine Severity and Frequency With Migraineguard ™</brief_title>
  <official_title>Migraineguard ™ Supplement Reduces the Severity and Frequency of Migraine , a Randomized, Placebo-controlled, Double-blind, Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Herbacure Natural</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Herbacure Natural</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Numerous treatments have been recommended for the prevention of migraine. The purpose of this&#xD;
      randomized double-blind placebo controlled trial was to assess the efficacy of MIGRAINEGUARD&#xD;
      ™ supplement by Herbacure Natural containing a combination of COQ10 , magnesium, riboflavin&#xD;
      ,feverfew , Skullcap and black pepper as prophylactic treatment for migraine.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Our team will assess MIGRAINEGUARD ™ , a migraine prevention supplement marketed Herbacure&#xD;
      Natural for individual suffering from multiple migraine attacks in one month . The purpose of&#xD;
      this 7-months , randomized, double-blind, placebo controlled study is to evaluate the&#xD;
      efficacy and safety of MIGRAINEGUARD ™ produced by Herbacure Natural , A Canadian company&#xD;
      based in Vancouver , BC , in reducing migraine headache severity and frequency of attacks&#xD;
      compared to placebo when used every day, as a preventative solution for migraine and to&#xD;
      assess and monitor the safety of its usage for adverse effects.&#xD;
&#xD;
      The primary end-point is the severity and the frequency reduction of migraine attacks. The&#xD;
      secondary end-points will be the existence of adverse reaction.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 1, 2020</start_date>
  <completion_date type="Actual">November 25, 2020</completion_date>
  <primary_completion_date type="Actual">October 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patient experiencing migraine attack reduction by at least 50 percent in one month .</measure>
    <time_frame>7 months</time_frame>
    <description>Number of patient experiencing migraine attack reduction by at least 50 percent in one month . Migraineurs with 50 percent migraine attack decrease are considered &quot;Responders&quot; to supplement.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Severity of migraine headache reduction after &amp; Months</measure>
    <time_frame>7 Months</time_frame>
    <description>Reduction of Migraine severity After 7 months of supplementation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Reactions</measure>
    <time_frame>7 months</time_frame>
    <description>Report of any adverse reaction due to supplementation during the study</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Migraine</condition>
  <condition>Headache</condition>
  <arm_group>
    <arm_group_label>MigraineGuard</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active supplement treatment , MigraineGuard capsule containing Coq10 , Magnesium ,Vit B2 , Skullcap Extract , Feverfew Extract , Piperine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo for MigraineGuard</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo capsules non identifiable from Migraineguard capsules were used as control comparator</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Migraineguard</intervention_name>
    <description>2 Capsules per day for 7 Months</description>
    <arm_group_label>MigraineGuard</arm_group_label>
    <arm_group_label>Placebo for MigraineGuard</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult aged 18 to 65 years Female and Male&#xD;
&#xD;
          -  Based on IHS criteria ,are diagnosed with migraine (criteria of the International&#xD;
             Classification of Headaches Disorders)&#xD;
&#xD;
          -  Individuals with minimum of 3 severe to extreme migraine attacks during the last 3&#xD;
             months .&#xD;
&#xD;
          -  Generally in good health&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Individuals taking any preventive treatment for migraine&#xD;
&#xD;
          -  Excessive usage of painkillers&#xD;
&#xD;
          -  Cancer &amp; Head injury and trauma&#xD;
&#xD;
          -  Any medical condition that may impact the validity of collected information&#xD;
&#xD;
          -  Previous usage of Botox within 6 months of study&#xD;
&#xD;
          -  Last week usage of triptans&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AMIR A DOWLATSHAHI, PHD</last_name>
    <role>Study Director</role>
    <affiliation>HERBACURE NATURAL INC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Herbacure Natural</name>
      <address>
        <city>Burnaby</city>
        <state>British Columbia</state>
        <zip>V3J 1N3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 13, 2021</study_first_submitted>
  <study_first_submitted_qc>February 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 17, 2021</study_first_posted>
  <last_update_submitted>March 16, 2021</last_update_submitted>
  <last_update_submitted_qc>March 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>migraine</keyword>
  <keyword>headache</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
    <mesh_term>Headache</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

